Results 91 to 100 of about 1,912,136 (307)
Early Retinal UCHL1 Dysregulation Coupled With Synaptic Loss Reflects Alzheimer's Disease Severity
This study identifies synapse‐enriched deubiquitinase UCHL1 as an early Aβ‐responsive regulator of retinal synaptopathy in Alzheimer's disease. Retinal UCHL1 loss accompanies excitatory synapse degeneration, p75NTR activation, and neuroinflammation, and predicts Braak stage and cognitive decline. Aβ42 fibrils trigger synaptic and UCHL1 depletion before
Altan Rentsendorj +25 more
wiley +1 more source
Economic Evaluation of Positron Emission Tomography (PET) in Non Small Cell Lung Cancer (NSCLC), CHERE Working Paper 2007/6 [PDF]
Background: There are several perceived benefits from introducing positron emission tomography (PET) scanning into the staging of non small lung cancer (NSCLC).
Stephen Goodall +2 more
core
Conjugated poly(imide dioxime)‐based microspheres establish a radiometal coordination‐driven conformational interlocked network with ultra‐high radiostability. This platform enables low‐temperature, multi‐radionuclide labeling for SPECT/PET/MRI imaging and radionuclide therapy. Mechanistic insights from EXAFS and DFT reveal enhanced stability, while in
Xiao Xu +10 more
wiley +1 more source
Nuclear blood pool imaging using radiolabeled red blood cells has been used in the clinical setting for the evaluation of a number of medical conditions including gastrointestinal hemorrhage, impaired cardiac contractility, and altered cerebrovascular ...
Shaowei Wang, Jung Choi
doaj +1 more source
Toward Personalized Theranostics: A Modular PET Platform for Antibody‐Based Imaging and Therapy
This modular, site‐specific antibody platform enables customizable conjugates for PET imaging and therapy. Interchangeable payloads – including radiometals, cytotoxics, and fluorophores – support adaptable, multimodal applications with limited off‐target effects. In vivo, the DFO/DOTAGA bischelate immunoconjugate provided clear tumor delineation in PET/
Delphine Vivier +16 more
wiley +1 more source
Similarly to the applications described in the first part of this publication, positron emission tomography with computed tomography (PET/CT) is also gaining importance in monitoring a tumour’s response to therapy and diagnosing breast cancer recurrences.
Elżbieta Jodłowska +6 more
doaj +1 more source
PET Radioligands for in Vivo Visualization of Neuroinflammation. [PDF]
Neuroinflammation is a well-orchestrated, dynamic, multicellular process playing a major role in neurodegenerative disorders. The microglia which make up the innate immune system of the central nervous system are key cellular mediators of ...
Ory, Dieter +4 more
core +1 more source
A novel hetero‐bivalent agent, 68Ga/177Lu‐FZ‐NF‐1, concurrently targets Nectin‐4 and FAP in triple‐negative breast cancer. It yields significant preclinical tumor regression and clinically identifies additional metastatic lesions missed by 18F‐FDG PET, demonstrating promising theranostic potential for personalized management.
Ye Li +13 more
wiley +1 more source
The PROMISE-V2 PRIMARY score and SULmax [18F]PSMA-1007 PET/CT in primary staging of prostate cancer
Introduction: The PRIMARY score of the PROMISE-V2 criteria for primary staging of prostate cancer (PCa) and its relationship with the maximum standardized uptake value normalized to lean body mass (SULmax) have not been evaluated.
J. Antonio Serna-Macias +4 more
doaj +1 more source
PET/CT en oncología pediátrica
Los exámenes metabólicos con PET (Positron Emission Tomography) han experimentado un notable desarrollo tecnológico y expansión de su uso clínico en las últimas décadas.
Dr. H. David Ladrón de Guevara
doaj +1 more source

